Education
About Us
Working with TipRanks
Follow Us
Jurriaan Dekkers Insider Profile
4 Followers
Jurriaan Dekkers, Chief Financial Officer at Faron Pharmaceuticals Oy, holds 0.00 shares in Faron Pharmaceuticals Oy (Ticker: GB:FARN). Most recently, Jurriaan Dekkers Sold 4,000 shares of Faron Pharmaceuticals Oy on Jan 13, 2026 for an estimated value of 7.29K .
Jurriaan Dekkers has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Jurriaan Dekkers does not currently own shares as a corporate insider.
A breakdown of Jurriaan Dekkers's holdings
Insider Roles
Chief Financial Officer
Roles that Jurriaan Dekkers holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Jurriaan Dekkers
Jurriaan Dekkers's Trading History
List of latest transactions for each holding click on a transaction to see Jurriaan Dekkers's performance on stock
You May Also Like
Jurriaan Dekkers insider profile FAQ
What is the percentage of profitable transactions made by Jurriaan Dekkers?
The percentage of profitable transactions made by Jurriaan Dekkers is ―.
What is the average return per transaction made by Jurriaan Dekkers?
The average return per transaction made by Jurriaan Dekkers is ―.
What stocks does Jurriaan Dekkers hold?
Jurriaan Dekkers holds: GB:FARN stocks.
What was Jurriaan Dekkers’s latest transaction?
Jurriaan Dekkers latest transaction was an Informative Sell of 7.29K .
What was Jurriaan Dekkers's most profitable transaction?
Jurriaan Dekkers’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Jurriaan Dekkers's role in Faron Pharmaceuticals Oy?
Jurriaan Dekkers's role in Faron Pharmaceuticals Oy is Chief Financial Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.